ASH 2020 | Autograft purity indicates multiple myeloma treatment efficacy
Susan Bal, MD, MBBS, O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, discusses the importance of autograft purity in lowering the incidence of measurable residual disease (MRD) in multiple myeloma. Two novel induction regimens in multiple myeloma, lenalidomide plus bortezomib plus dexamethasone (VRd) and carfilzomib plus lenalidomide plus dexamethasone (KrD), were compared for autograft purity. The study found that KrD was able to produce a cleaner autograft and had a higher proportion of patients achieving an MRD graft. Further research is needed to evaluate whether increased autograft purity will affect long term progression-free survival (PFS) and overall survival (OS) rates. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
